The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 24, 2017

Filed:

Sep. 13, 2010
Applicants:

Silke Aigner, Frankenthal, DE;

Matthias Germer, Langen, DE;

Frank Osterroth, Dietzenbach, DE;

Christoph Uherek, Seligenstadt, DE;

Elmar Kraus, Bad Vilbel, DE;

Andrea Wartenberg-demand, Linden, DE;

Daniele Wolf, Dreieich, DE;

Sibylle Kaiser, Zwingenberg, DE;

Juergen Lindner, Frankfurt, DE;

Christoph Bruecher, Eschborn, DE;

Benjamin Daelken, Frankfurt am Main, DE;

Gregor Schulz, Umkirch, DE;

Inventors:

Silke Aigner, Frankenthal, DE;

Matthias Germer, Langen, DE;

Frank Osterroth, Dietzenbach, DE;

Christoph Uherek, Seligenstadt, DE;

Elmar Kraus, Bad Vilbel, DE;

Andrea Wartenberg-Demand, Linden, DE;

Daniele Wolf, Dreieich, DE;

Sibylle Kaiser, Zwingenberg, DE;

Juergen Lindner, Frankfurt, DE;

Christoph Bruecher, Eschborn, DE;

Benjamin Daelken, Frankfurt am Main, DE;

Gregor Schulz, Umkirch, DE;

Assignee:

BIOTEST AG, Dreieich, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2812 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.


Find Patent Forward Citations

Loading…